-

Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference

WALTHAM, Mass.--(BUSINESS WIRE)--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences.

Scios 3 FIB-SEM offers high-powered versatility
The Thermo Scientific™ Scios™ 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with automation to dramatically improve site-specific quality control. The Scios 3 FIB-SEM offers increased productivity for both industry and academia with enhanced lamella preparation, due to advances in FIB column performance. Ease-of-use upgrades will benefit microscopists of all experience levels.

“Researchers across the globe seek new and better materials for various applications – from clean energy and aerospace to productivity of digital devices,” said David Wall, vice president and general manager of materials science for Thermo Fisher. “The current pace of the development of new materials and their increasing complexity poses significant challenges, and Scios 3 addresses those challenges head-on with world-class advancements designed to serve both academia and industry.”

With advanced automation and high-throughput, Scios 3 improves ease of use, reliability and productivity. To learn more, stop by booth #1734 at M&M for a live demonstration or visit thermofisher.com/scios3.

Talos 12 adapts to researchers across disciplines and experience levels
Thermo Fisher has evolved the popular Talos transmission electron microscope (TEM) design, culminating in the Thermo Scientific Talos™ 12 TEM, making leading-edge sample analysis more accessible than ever for biological research, pathology and drug development.

“We’re pleased to introduce Talos 12 at M&M this year to bring transmission electron microscopy to more researchers,” said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. “A wide array of laboratories can now benefit from this adaptable 120kV instrument. Not only does the reduced footprint and next-generation enclosure fit into more lab spaces, but the streamlined workflows – from routine imaging of cells and tissues to AI-assisted sample characterization to cryo-EM – enable the user-friendly Talos 12 to support remote operation for collaboration regardless of location.”

TEM systems often require highly skilled specialists, but Talos 12 lowers those requirements with new enhancements to improve ease of use while maintaining high quality imaging with high reproducibility. To learn more, stop by booth #1734 at M&M for a live demonstration or visit thermofisher.com/talos12.

Stop by booth #1734 to see Scios, Talos and more
Thermo Fisher will have a significant presence at the Salt Palace Convention Center. In addition to live demonstrations of Scios 3 and Talos 12, several other industry-leading solutions will be on full display.

Stop by booth #1734 to engage with Thermo Fisher subject-matter experts as they discuss the latest advancements in microscopy innovation and analytical research technology.

Additionally, Thermo Fisher has hosted a “Women in Microscopy” breakfast at M&M for more than two decades and will continue that tradition at the Hyatt Regency on the morning of July 30. Dr. Amelia Dempere, Director of the Nanoscale Research Facility (NRF) at the University of Florida, will talk about her career journey and the ever-increasing importance of women in research.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom